New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of...

Related Keywords

Japan , South Korea , China , Sweden , Massachusetts , United States , Israel , Australia , United Kingdom , Canada , Stockholm , Uppsala , Uppsala Lan , Switzerland , Boston , Swedish , Great Britain , Jiang Millington , Oskar Bosson , Drug Administration , National Institute On , Alzheimer Clinical Trial Consortium , Ministry Of Health , Uppsala University , Novel Subcutaneous Administration , Vp Communications , Washington University School Of Medicine , National Institutes Of Health , Alzheimer Network Trials Unit , Eisai Co Ltd , Nasdaq Stockholm , Late Breaking Symposium , Early Alzheimer , Long Term Outcomes , Predictive Biomarkers , Novel Subcutaneous , Clinical Trials , Biologics License Application , Clinical Dementia Rating , Director Corporate Communication , Social Media , Innovative Licensing , Access Pathway , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Bioarctic ,